title: irRECIST and iRECIST: the devil is in the details.
authors.affiliation: Departments of Clinical Research and Innovation.
authors.forename: J
authors.initials: J
authors.lastname: Le Lay
authors.affiliation: Imaging Centre Oscar Lambret, Lille.
authors.forename: H
authors.initials: H
authors.lastname: Jarraya
authors.affiliation: Department of Cancerology, Medical School, Lille University, Lille.
authors.forename: L
authors.initials: L
authors.lastname: Lebellec
authors.affiliation: Departments of Clinical Research and Innovation.|Medical Oncology Department, Centre Oscar Lambret, Lille, France.
authors.forename: N
authors.initials: N
authors.lastname: Penel
mesh_terms: D000074322:Antineoplastic Agents, Immunological / Q000627:therapeutic use*; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors; D017322:Clinical Trials, Phase II as Topic / Q000379:methods; D017326:Clinical Trials, Phase III as Topic / Q000379:methods; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors; D066066:Response Evaluation Criteria in Solid Tumors; D016896:Treatment Outcome
chemical_list: D000074322:Antineoplastic Agents, Immunological; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor